Lessons from a genomewide association study of rheumatoid arthritis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Role of LncRNA-AF085935, IL-10 and IL-17 in Rheumatoid Arthritis Patients With Chronic Hepatitis C.Journal of clinical medicine research · 2017
   Article
2. Clinical features and functional significance of the P369S/R408Q variant in pyrin, the familial Mediterranean fever protein.Annals of the rheumatic diseases · 2010
   Article
3. Anticitrullinated protein/peptide antibodies in rheumatoid arthritis.Deutsches Arzteblatt international · 2009
   Article
4. Rheumatoid arthritis and smoking: putting the pieces together.Arthritis research & therapy · 2009
   Review

Corrections and comments

• Comment on
  TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study.2007

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as